Is premenstrual dysphoric disorder a distinct clinical entity?

Jean Endicott, Jay Amsterdam, Elias Eriksson, Ellen Frank, Ellen Freeman, Robert Hirschfeld, Frank Ling, Barbara Parry, Teri Pearlstein, Jerrold Rosenbaum, David Rubinow, Peter Schmidt, Sally Severino, Meir Steiner, Donna E. Stewart, Susan Thys-Jacobs

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Does the evidence now available support the concept of premenstrual dysphoric disorder (PMDD) as a distinct clinical disorder such that the relative safety and efficacy of potential treatment can be evaluated? In a roundtable discussion of this question, a wealth of information was reviewed by a panel of experts. The key characteristics of PMDD, with clear onset and offset of symptoms closely linked to the menstrual cycle and the prominence of symptoms of anger, irritability, and internal tension, were contrasted with those of known mood and anxiety disorders. PMDD displays a distinct clinical picture that, in the absence of treatment, is remarkably stable from cycle to cycle and over time. Effective treatment of PMDD can be accomplished with serotinergic agents. At least 60% of patients respond to selective serotonin reuptake inhibitors (SSRIs). In comparison with other disorders, PMDD symptoms respond to low doses of SSRIs and to intermittent dosing. Normal functioning of the hypothalamic-pituitary-adrenal (HPA) axis, biologic characteristics generally related to the serotonin system, and a genetic component unrelated to major depression are further features of PMDD that separate it from other affective (mood) disorders. Based on this evidence, the consensus of the group was that PMDD is a distinct clinical entity. Potential treatments for this disorder can now be evaluated on this basis to meet the clear need for effective therapy.

Original languageEnglish (US)
Pages (from-to)663-679
Number of pages17
JournalJournal of Women's Health and Gender-Based Medicine
Volume8
Issue number5
StatePublished - Jun 1999

Fingerprint

Mood Disorders
Serotonin Uptake Inhibitors
Anger
Therapeutics
Menstrual Cycle
Premenstrual Dysphoric Disorder
Anxiety Disorders
Serotonin
Consensus
Depression
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Endicott, J., Amsterdam, J., Eriksson, E., Frank, E., Freeman, E., Hirschfeld, R., ... Thys-Jacobs, S. (1999). Is premenstrual dysphoric disorder a distinct clinical entity? Journal of Women's Health and Gender-Based Medicine, 8(5), 663-679.

Is premenstrual dysphoric disorder a distinct clinical entity? / Endicott, Jean; Amsterdam, Jay; Eriksson, Elias; Frank, Ellen; Freeman, Ellen; Hirschfeld, Robert; Ling, Frank; Parry, Barbara; Pearlstein, Teri; Rosenbaum, Jerrold; Rubinow, David; Schmidt, Peter; Severino, Sally; Steiner, Meir; Stewart, Donna E.; Thys-Jacobs, Susan.

In: Journal of Women's Health and Gender-Based Medicine, Vol. 8, No. 5, 06.1999, p. 663-679.

Research output: Contribution to journalArticle

Endicott, J, Amsterdam, J, Eriksson, E, Frank, E, Freeman, E, Hirschfeld, R, Ling, F, Parry, B, Pearlstein, T, Rosenbaum, J, Rubinow, D, Schmidt, P, Severino, S, Steiner, M, Stewart, DE & Thys-Jacobs, S 1999, 'Is premenstrual dysphoric disorder a distinct clinical entity?', Journal of Women's Health and Gender-Based Medicine, vol. 8, no. 5, pp. 663-679.
Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R et al. Is premenstrual dysphoric disorder a distinct clinical entity? Journal of Women's Health and Gender-Based Medicine. 1999 Jun;8(5):663-679.
Endicott, Jean ; Amsterdam, Jay ; Eriksson, Elias ; Frank, Ellen ; Freeman, Ellen ; Hirschfeld, Robert ; Ling, Frank ; Parry, Barbara ; Pearlstein, Teri ; Rosenbaum, Jerrold ; Rubinow, David ; Schmidt, Peter ; Severino, Sally ; Steiner, Meir ; Stewart, Donna E. ; Thys-Jacobs, Susan. / Is premenstrual dysphoric disorder a distinct clinical entity?. In: Journal of Women's Health and Gender-Based Medicine. 1999 ; Vol. 8, No. 5. pp. 663-679.
@article{03f0bc7042354530a9fc85c76e685d18,
title = "Is premenstrual dysphoric disorder a distinct clinical entity?",
abstract = "Does the evidence now available support the concept of premenstrual dysphoric disorder (PMDD) as a distinct clinical disorder such that the relative safety and efficacy of potential treatment can be evaluated? In a roundtable discussion of this question, a wealth of information was reviewed by a panel of experts. The key characteristics of PMDD, with clear onset and offset of symptoms closely linked to the menstrual cycle and the prominence of symptoms of anger, irritability, and internal tension, were contrasted with those of known mood and anxiety disorders. PMDD displays a distinct clinical picture that, in the absence of treatment, is remarkably stable from cycle to cycle and over time. Effective treatment of PMDD can be accomplished with serotinergic agents. At least 60{\%} of patients respond to selective serotonin reuptake inhibitors (SSRIs). In comparison with other disorders, PMDD symptoms respond to low doses of SSRIs and to intermittent dosing. Normal functioning of the hypothalamic-pituitary-adrenal (HPA) axis, biologic characteristics generally related to the serotonin system, and a genetic component unrelated to major depression are further features of PMDD that separate it from other affective (mood) disorders. Based on this evidence, the consensus of the group was that PMDD is a distinct clinical entity. Potential treatments for this disorder can now be evaluated on this basis to meet the clear need for effective therapy.",
author = "Jean Endicott and Jay Amsterdam and Elias Eriksson and Ellen Frank and Ellen Freeman and Robert Hirschfeld and Frank Ling and Barbara Parry and Teri Pearlstein and Jerrold Rosenbaum and David Rubinow and Peter Schmidt and Sally Severino and Meir Steiner and Stewart, {Donna E.} and Susan Thys-Jacobs",
year = "1999",
month = "6",
language = "English (US)",
volume = "8",
pages = "663--679",
journal = "Journal of Women's Health",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Is premenstrual dysphoric disorder a distinct clinical entity?

AU - Endicott, Jean

AU - Amsterdam, Jay

AU - Eriksson, Elias

AU - Frank, Ellen

AU - Freeman, Ellen

AU - Hirschfeld, Robert

AU - Ling, Frank

AU - Parry, Barbara

AU - Pearlstein, Teri

AU - Rosenbaum, Jerrold

AU - Rubinow, David

AU - Schmidt, Peter

AU - Severino, Sally

AU - Steiner, Meir

AU - Stewart, Donna E.

AU - Thys-Jacobs, Susan

PY - 1999/6

Y1 - 1999/6

N2 - Does the evidence now available support the concept of premenstrual dysphoric disorder (PMDD) as a distinct clinical disorder such that the relative safety and efficacy of potential treatment can be evaluated? In a roundtable discussion of this question, a wealth of information was reviewed by a panel of experts. The key characteristics of PMDD, with clear onset and offset of symptoms closely linked to the menstrual cycle and the prominence of symptoms of anger, irritability, and internal tension, were contrasted with those of known mood and anxiety disorders. PMDD displays a distinct clinical picture that, in the absence of treatment, is remarkably stable from cycle to cycle and over time. Effective treatment of PMDD can be accomplished with serotinergic agents. At least 60% of patients respond to selective serotonin reuptake inhibitors (SSRIs). In comparison with other disorders, PMDD symptoms respond to low doses of SSRIs and to intermittent dosing. Normal functioning of the hypothalamic-pituitary-adrenal (HPA) axis, biologic characteristics generally related to the serotonin system, and a genetic component unrelated to major depression are further features of PMDD that separate it from other affective (mood) disorders. Based on this evidence, the consensus of the group was that PMDD is a distinct clinical entity. Potential treatments for this disorder can now be evaluated on this basis to meet the clear need for effective therapy.

AB - Does the evidence now available support the concept of premenstrual dysphoric disorder (PMDD) as a distinct clinical disorder such that the relative safety and efficacy of potential treatment can be evaluated? In a roundtable discussion of this question, a wealth of information was reviewed by a panel of experts. The key characteristics of PMDD, with clear onset and offset of symptoms closely linked to the menstrual cycle and the prominence of symptoms of anger, irritability, and internal tension, were contrasted with those of known mood and anxiety disorders. PMDD displays a distinct clinical picture that, in the absence of treatment, is remarkably stable from cycle to cycle and over time. Effective treatment of PMDD can be accomplished with serotinergic agents. At least 60% of patients respond to selective serotonin reuptake inhibitors (SSRIs). In comparison with other disorders, PMDD symptoms respond to low doses of SSRIs and to intermittent dosing. Normal functioning of the hypothalamic-pituitary-adrenal (HPA) axis, biologic characteristics generally related to the serotonin system, and a genetic component unrelated to major depression are further features of PMDD that separate it from other affective (mood) disorders. Based on this evidence, the consensus of the group was that PMDD is a distinct clinical entity. Potential treatments for this disorder can now be evaluated on this basis to meet the clear need for effective therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032849231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032849231&partnerID=8YFLogxK

M3 - Article

C2 - 10839653

AN - SCOPUS:0032849231

VL - 8

SP - 663

EP - 679

JO - Journal of Women's Health

JF - Journal of Women's Health

SN - 1540-9996

IS - 5

ER -